GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » 3-Year EPS without NRI Growth Rate

Molecular Partners AG (XSWX:MOLN) 3-Year EPS without NRI Growth Rate : 9.40% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG 3-Year EPS without NRI Growth Rate?

Molecular Partners AG's EPS without NRI for the three months ended in Dec. 2023 was CHF-0.47.

During the past 12 months, Molecular Partners AG's average EPS without NRI Growth Rate was -149.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Molecular Partners AG was 9.40% per year. The lowest was -154.90% per year. And the median was -20.50% per year.


Competitive Comparison of Molecular Partners AG's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Molecular Partners AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's 3-Year EPS without NRI Growth Rate falls into.



Molecular Partners AG 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Molecular Partners AG  (XSWX:MOLN) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Molecular Partners AG 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Industry
Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus